title: Lack of chronic toxicity and carcinogenicity of dietary administrated catechin mixture in Wistar Hannover GALAS rats.
abstract: Chronic toxicity and carcinogenicity of catechin mixture were examined in Wistar Hannover GALAS rats. Administration was in the diet at concentrations of 0, 0.02, 0.3, 1 or 3%. Slight increases in relative liver weight and centrilobular hypertrophy of hepatocytes associated with induction of CYP3A2 were found at the 3% in males of both studies. However, because there were no signs indicative of hepatotoxicity on serum biochemical and histopathological examinations, the changes observed in the liver were regarded as adaptation, and not adverse effects. The slight depressions of body weights at the 3% in females of the chronic toxicity study and in both sexes of the carcinogenicity study were observed. These decreases were because the diet at the highest concentration was frangible and nominal food consumption may not have reflected the actual food consumption resulting in decrease in caloric intake, rather than toxic effects. Thus it was concluded that catechin mixture had no toxicity. In addition, tumor incidences and types were comparable between treated and control groups. Based on the results, the no observed adverse effect levels estimated from the chronic toxicity study were 3% in both sexes equal to 1922.9 in males and 2525.7 mg/kg/day in females. Catechin mixture has no carcinogenic potential in male and female rats.
authors.affiliation: National Institute of Health Sciences, 1-18-1 Kamiyoga, Tokyo 158-8501, Japan. midoriy@nihs.go.jp
authors.forename: Midori
authors.initials: M
authors.lastname: Yoshida
authors.forename: Miwa
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kaoru
authors.initials: K
authors.lastname: Inoue
authors.forename: Dai
authors.initials: D
authors.lastname: Nakae
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Nishikawa
mesh_terms: D000821:Animal Feed; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D002273:Carcinogens / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D002392:Catechin / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis; D004435:Eating / Q000187:drug effects; D004790:Enzyme Induction; D005260:Female; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008136:Longevity / Q000187:drug effects; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis; D009369:Neoplasms / Q000209:etiology / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D036401:Toxicity Tests, Chronic
chemical_list: D000975:Antioxidants; D002273:Carcinogens; D008565:Membrane Proteins; D002392:Catechin; C465260:Cyp3a2 protein, rat; D051544:Cytochrome P-450 CYP3A